Drug intelligence / Profile preview

alectinib + osimertinib

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

A combination of two targeted therapies used primarily for the treatment of non-small cell lung cancer (NSCLC) with specific genetic alterations. Alectinib is an ALK tyrosine kinase inhibitor that targets ALK rearrangements, while osimertinib is a third-generation EGFR tyrosine kinase inhibitor that targets EGFR mutations, particularly those with T790M resistance mutations. This combination has shown effectiveness in treating patients with concurrent EGFR and ALK alterations, especially in cases of resistance to single-agent therapy and in managing brain metastases.

Brand names: TagrissoAlecensa
Other names: osimertinib plus alectinibosimertinib and alectinib

Targets

EGFR (Epidermal growth factor receptor)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on alectinib + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alectinib + osimertinib.

Explore the full profile